Clinical Trials Browser

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03425565 2024-04-12

PEACOCC

Phase 2 Unknown

48 enrolled

Gynecologic

Clear Cell Tumor

NCT05708950 2023-07-13

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Phase 1/2 Unknown

314 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms

NCT03410784 2023-03-24

MITO28MaNGOov4

Phase 2 Unknown

72 enrolled

Gynecologic

Ovarian Neoplasms

NCT05761132 2023-03-09

Apollo

Phase 2 Unknown

40 enrolled

Gynecologic

Vulvar Neoplasms, Neoplasms, Squamous Cell

NCT03430700 2023-01-30

PROMPT

Phase 2 Unknown

28 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04641728 2022-08-09

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Phase 2 Unknown

28 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04460456 2022-06-30

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Phase 1 Unknown

58 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05158062 2022-04-26

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Phase 2 Unknown

35 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT04375956 2021-12-20

MITO 27

Phase 2 Unknown

100 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04238988 2021-08-27

MITO CERV 3

Phase 2 Unknown

45 enrolled

Gynecologic

Locally Advanced Cervical Cancer

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04303884 2020-03-11

CR-GTP

Phase 2 Unknown

15 enrolled

Gynecologic

Gestational Trophoblastic Disease

NCT03539328 2018-05-29

MITO27

Phase 2 Unknown

138 enrolled

Gynecologic

Ovarian Neoplasms

Clinical Trials

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

PEACOCC

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

MITO28MaNGOov4

Apollo

PROMPT

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

MITO 27

MITO CERV 3

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

CR-GTP

MITO27